Does aliskiren 150 mg improve neurohumoral biomarkers in patients with symptomatic heart failure?
Aliskiren 150 mg added to standard heart failure therapy improves neurohumoral biomarkers over 12 weeks, independent of concomitant mineralocorticoid receptor antagonist use.
Aliskiren 150 mg added to standard HF therapy was well tolerated over 12 weeks and provided beneficial changes in neurohumoral biomarkers regardless of concomitant MRA treatment.
Pitt et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: